Abstract: Provided herein is an engineered extracellular vesicle (eEV) and an extracellular vesicle delivery vehicle. The engineered extracellular vesicle is an isolated extracellular vesicle that has a membrane hybridized with lipids. The extracellular vesicle delivery vehicle is a lipid-hybridized extracellular vesicle with a nucleic acid loaded within the core, a multi-layered polyelectrolyte coating deposited around the lipid-hybridized extracellular vesicle and a therapeutic drug complexed to one of the layer of polyelectrolyte coatings. Also provided are methods for preparing an engineered extracellular vesicle, for preparing an extracellular vesicle delivery vehicle, for treating a pathophysiological condition in a subject, and for co-delivering a nucleic acid and a therapeutic drug to a cell of interest.

Abstract: The presently disclosed subject matter provides compositions, methods, and kits comprising shape memory particles that can be used for delivering a drug and/or treating a disease or disorder in a patient. Specifically, shape changes in the presently disclosed shape memory particles can be used to control drug delivery spatially and/or temporally in a patient. Also provided are compositions, methods, and kits comprising nanoparticles and hypoxia-inducible factor (HIF) inhibitors with or without chemotherapeutic agents for inhibiting HIF activity in a patient and/or treating a hypoxia-associated disease or disorder.

Abstract: The presently disclosed subject matter provides compositions, methods, and kits comprising shape memory particles that can be used for delivering a drug and/or treating a disease or disorder in a patient. Specifically, shape changes in the presently disclosed shape memory particles can be used to control drug delivery spatially and/or temporally in a patient. Also provided are compositions, methods, and kits comprising nanoparticles and hypoxia-inducible factor (HIF) inhibitors with or without chemotherapeutic agents for inhibiting HIF activity in a patient and/or treating a hypoxia-associated disease or disorder.

Abstract: A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disulfide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.

Abstract: A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disuifide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.

Abstract: A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disulfide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.

Abstract: A method for determining a physiological characteristic of a patient on which a medical device is applied is disclosed. Electric current data is obtained from the medical device. The electric current data is filtered to produce filtered data. The physiological characteristic is determined based on the filtered data.